Compare BXMX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXMX | ATAI |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2021 |
| Metric | BXMX | ATAI |
|---|---|---|
| Price | $14.01 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.57 |
| AVG Volume (30 Days) | 142.4K | ★ 4.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $285.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.25 | $1.15 |
| 52 Week High | $15.00 | $6.73 |
| Indicator | BXMX | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 46.06 |
| Support Level | $13.70 | $3.41 |
| Resistance Level | $14.02 | $4.32 |
| Average True Range (ATR) | 0.21 | 0.25 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 15.00 | 27.82 |
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options of writing index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.